Achilles Therapeutics : Results of Annual General Meeting Form 6 K
June 27, 2024 at 09:07 pm
Share
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2024
Commission File Number: 001-40299
Achilles Therapeutics plc
(Exact name of registrant as specified in its charter)
245 Hammersmith Road
London W6 8PW
United Kingdom
Tel: +44 (0)20 8154 4600
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Results of Annual General Meeting
On June 25, 2024, Achilles Therapeutics plc ("Achilles" or the "Company") held its 2024 Annual General Meeting (the "Annual General Meeting"), and all resolutions were passed as proposed. At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on May 24, 2024 were duly proposed and passed on a poll.
The matters presented for a vote and the related results are as follows:
Ordinary Resolutions
For
Against
Abstain
To re-elect Edwin Moses as a Director of the Company.
6,756,604
190,295
11,167,811
To re-elect Iraj Ali as a Director of the Company.
6,798,071
150,222
11,166,417
To re-elect Carsten Boess as a Director of the Company.
6,803,027
143,394
11,168,289
To re-elect Bernhard Ehmer as a Director of the Company.
6,808,607
137,814
11,168,289
To re-elect Michael Giordano as a Director of the Company.
6,720,495
142,294
11,251,921
To re-elect Julie O'Neill as a Director of the Company.
6,796,562
149,859
11,168,289
To re-appoint KPMG LLP as UK statutory auditors of the Company, to hold office until the conclusion of the next Annual General Meeting.
6,898,359
27,858
11,188,493
To authorize the Company's Audit Committee to determine the Company's auditors' remuneration for the fiscal year ending December 31, 2024.
6,888,016
58,323
11,168,371
To receive the UK statutory annual accounts and report for the fiscal year ended 31 December 2023 and to note that the Directors do not recommend the payment of any dividend for the year ended December 31, 2023.
6,882,217
56,252
11,176,241
To receive and approve, on a non-binding, advisory basis, the Company's UK statutory Directors' Remuneration Report for the year ended December 31, 2023.
4,513,763
2,423,898
11,177,049
The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to shareholders on May 24, 2024 and furnished as an exhibit to a Form 6-K filed with the U.S. Securities and Exchange Commission on May 24, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ACHILLES THERAPEUTICS PLC
Date: June 27, 2024
By:
/s/ Robert Coutts
Robert Coutts
Chief Financial Officer
Attachments
Original Link
Permalink
Disclaimer
Achilles Therapeutics plc published this content on
27 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
27 June 2024 20:06:54 UTC.
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.